NCT04820673View on ClinicalTrials.gov

Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

March 9, 2021

Primary Completion Date

May 4, 2022

Study Completion Date

May 4, 2022

Conditions
Acne Vulgaris
Interventions
DRUG

Sarecycline

Clinicians will prescribe the sarecycline as per their own clinical judgment and standard practice.

Trial Locations (2)

11201

Almirall Site #1, Brooklyn

02116

Almirall Site#2, Boston

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY